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Purpose: Most patients, even some urologists, assume that prostate volume is the most 
important prognostic factor for lower urinary tract symptoms (LUTS). In some cases, 
however, prostatic inflammation is a more important factor in LUTS than is prostate 
volume. For this reason, comparison of the impact on LUTS of inflammation and pros-
tate volume is an attractive issue.
Materials and Methods: From January 2000 to May 2009, 1,065 men aged between 47 
and 91 years (who underwent transrectal ultrasound-guided prostate needle biopsy 
and transurethral prostatectomy) were retrospectively investigated. Components such 
as age, serum prostate-specific antigen (PSA) level, prostate volume, and the presence 
of prostatitis were investigated through independent-sample t-tests, chi-square tests, 
and univariate and multivariate analyses.
Results: Chi-square tests between prostatitis, prostate volume, serum PSA, and severe 
LUTS showed that prostate volume (R=0.173; p=0.041) and prostatitis (R=0.148; p
＜0.001) were related to LUTS. In particular, for a prostate volume under 50 ml, prosta-
titis was a stronger risk factor than was prostate volume. Among the multivariate pre-
dictors, prostatitis (odds ratio [OR]: 1.945; p＜0.001) and prostate volume (OR, 1.029; 
p＜0.001) were found to be aggravating factors of LUTS. 
Conclusions: For patients with prostate volume less than 50 ml, prostatitis was found 
to be a more vulnerable factor for LUTS. For those with prostate volume over 50 ml, 
on the other hand, the volume itself was a more significant risk factor than was 
prostatitis. In conclusion, the presence of prostatitis is one of the risk factors for LUTS 
with increased prostate volume.
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is an increasingly 
common condition in aged males. By the age of 60 years, 
more than 50% of men will have microscopic evidence of the 
disease, and more than 40% of men beyond this age will 
have lower urinary tract symptoms (LUTS) [1]. Many risk 
factors may lead to progression of LUTS, for instance, pros-
tate volume, metabolic syndrome, and inflammation [2-4]. 
In particular, inflammation of the prostate is an emerging 
constituent of BPH and LUTS [5]. It is difficult and compli-
cated to prioritize these risk factors. For practitioners, 
however, the priority is clinically critical. 
Prostate hyperplasia triggers bladder outlet obstruction 
and this obstruction disturbs urine outflow. Several struc-
tural and functional changes, for instance, collagen predis-
position and fibrosis in the detrusor muscle, are regarded 
in part as a positive compensatory response aiming to over-
come resistance to bladder empting [6,7]. To prevent these 
disasters, the operative management of BPH is an in-
evitable treatment choice unless the patient ignores incon-
venient catheterization [8]. However, patients with nor-
mal or even small prostate volumes complain of a similar 
degree of LUTS as do BPH patients, who do not complain Korean J Urol 2012;53:109-113
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TABLE 1. Characteristics of the patients 
Characteristic
Prostatitis 
patients
(group A)
No prostatitis 
patients
(group B)
p-value
Total population 
Age (yr)
sPSA (ng/ml) 
Mean prostate volume (ml)
321 (30.1)
73.28±9.26
10.95±8.71
43.10±21.14
744 (69.9)
68.02±5.39
11.17±8.57
41.19±20.96
-
0.052
0.170
0.369
Values are presented as number (%) or mean±SD.
sPSA, serumprostate-specific antigen.
TABLE 2. Odds ratio according to prostate volume. 
Prostate 
volume (ml) 
Population Ave.  IPSS  p-value  OR 
Confidence interval 
Lower Upper
-20
a
20-29 
30-39
40-49 
50-59 
60-69 
70-79 
60 
307 
189 
251 
37 
89 
59 
16.72±6.51 
19.32±8.83 
20.35±7.98 
20.94±6.79 
22.41±6.09 
24.90±5.95 
24.89±5.43 
 - 
 0.300 
 0.133 
 0.085 
＜0.001
b
＜0.001
b
＜0.001
b
- 
1.353 
1.588 
1.666 
6.751 
10.012 
5.697 
-
0.764
0.868
0.932
2.419
4.479
2.536
  2.396
  2.905
  2.980
18.839
22.380
12.797
Values are presented as number (%) or mean±SD.
Ave, average; IPSS, International Prostate Symptom Score.
a: reference variable, 
b: p＜0.05. 
that much. Thus, it is certain that many other factors influ-
ence LUTS.
Chronic prostatitis is one of the most common urologic 
diseases of 30 to 40-year-old men [9]. There have been abun-
dant discussions about prostatitis, but the particularity of 
this inflammatory disorder is hard to control and the re-
currence rate is over 20 to 30% [10]. Chronic prostatitis is 
one of the obvious causes of BPH itself and its symptoms 
overlap in many cases of BPH patients. Accordingly [11], 
it is hard to differentiate prostatitis from BPH and to weigh 
the gravity of these symptoms.
In many cases of patients with LUTS, the diagnostic and 
therapeutic approach should be directed to the prostate en-
largement or prostatitis. However, it is hard to separate 
most patients by prostatitis and BPH. For that reason, 
comparison of the effects of prostatitis and prostate en-
largement on LUTS is important to both urologists and 
patients.
MATERIALS AND METHODS
From January 2000 to May 2009, after the exclusion of pa-
tients with psychological problems, neurogenic bladder, 
asymptomatic elevation of prostate-specific antigen (PSA), 
acute prostatitis, and prostate cancer, 1,065 male patients 
aged between 47 and 91 years with LUTS who underwent 
transrectal prostate biopsy and transurethral prostatec-
tomy were enrolled in this study retrospectively. Not only 
general considerations such as age, height, and body 
weight but also International Prostate Symptom Score 
(IPSS), PSA, and prostate volume measured by transrectal 
ultrasonography were documented. Prostatitis was patho-
logically defined as significant lymphocytic infiltrate in the 
stroma immediately adjacent to the prostatic acini and con-
firmed by pathologic consultation. Pathologically un-
certain specimens were discussed and confirmed by two or 
more pathologists for therapeutic guidance. Patients with 
prostatitis were classified into group A and patients with-
out prostatitis (no prostatitis) were classified into group B. 
For statistical consideration, severe LUTS was defined as 
patients with IPSS over 20, and mild LUTS as a score under 
7.
We used independent-sample t-tests to compare IPSS 
with prostate volume and chi-square tests and logistic re-
gression analysis to compare the relative risk of prostate 
volume, prostatitis, and PSA. Technical statistics were 
performed by use of SPSS ver. 12.0 (SPSS Inc., Chicago, IL, 
USA).
RESULTS
The enrolled subjects were 1,065 men, their mean age was 
73.28±0.31 years old, the average PSA was 11.11±0.26 
ng/ml, and the average prostate volume was 41.77±0.64 ml. 
group A included 321 patients (30.1%), and group B in-
cluded 744 (69.9%). The average PSA was 10.95±8.71 ng/ml 
in group A and 11.17±8.57 ng/ml in group B (Table 1). The 
PSA of group B was slightly higher and the difference was 
statistically significant, though weakly. Chi-square tests 
between prostatitis, prostate volume, and PSA showed 
prostate volume and prostatitis to be significant risk fac-
tors for severe LUTS (p=0.041, p＜0.001). In particular, 
when respective IPSS values were compared with each 
count of prostate volume or presence of prostatitis, the rela-
tive risk of prostate volume was exclusively higher (R= 
0.148) and there was statistical significance for any level 
of prostate volume over 50 ml on the t-test (p＜0.001). Korean J Urol 2012;53:109-113
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TABLE 3. Comparison of average IPSS between prostate volume 
and prostatitis 
Prostate 
volume (ml) 
Ave. IPSS of 
patients
with prostatitis 
(group A)
Ave. IPSS of 
patients without 
prostatitis
(group B)
p-value
-20
20-29
30-39
40-49
50-59
60-69
70-79
80-
Total
a
18.91±7.71
20.59±9.19
21.81±7.30
22.83±6.87
24.08±5.64
27.23±6.51
27.06±5.81
25.94±7.03
22.86±7.80
16.22±6.19
18.82±8.66
19.75±8.22
20.12±6.61
19.07±5.75
23.75±5.34
23.98±5.05
25.98±7.54
20.37±7.80
0.039
a
＜0.001
a
0.028
a
0.030
a
0.075
0.122
0.120
0.170
＜0.001
Values are presented as mean±SD.
Ave, average; IPSS, International Prostate Symptom Score.
a: p＜0.05.
However, stepwise volume-controlled analysis showed no 
statistically significant difference between prostate vol-
ume and the severity of LUTS under 50 ml (Table 2). For 
that range of prostate volume, prostatitis instead showed 
statistical significance (Table 3). 
Univariate analysis of the risk factors for severe LUTS 
indicated that there was a statistically significant correla-
tion between severe LUTS and prostatitis and prostate vol-
ume (odds ratios [OR], 1.967 [1.492 to 2.592] and 1.029 
[1.022 to 1.037]; p＜0.001). The multivariate analysis 
showed this also (odds ratios, 1.945 [1.464 to 2.586] and 
1.029 [1.022 to 1.037]; p＜0.001). PSA, however, was not 
a statistically significant risk factor (OR, 1.018 [0.879 to 
1.013]; p=0.089). 
DISCUSSION
There are so many factors influencing LUTS that physi-
cians cannot target the patient’s symptoms all at once. 
Previous studies have revealed a relationship between 
LUTS and obesity, metabolic syndrome, smoking, alcohol 
consumption, and urinary tract infection. The Veterans 
Administration Normative Aging Study reported that in-
creased body mass index was a significant predictor of a 
clinical diagnosis of BPH [12,13]. Patients who complain 
of LUTS have not only one risk factor but also a list of com-
plex problems. Some of them can be managed by lifestyle 
modification or counseling only. On the other hand, asser-
tive treatment is inevitable for other risk factors such as 
bladder outlet obstruction by prostate hyperplasia.
Most of all, prostate enlargement is the most important 
factor for male LUTS management. It is the first consid-
eration of urologic clinical research on adult male LUTS 
without physiologic or neurologic problems. In autopsy 
studies, histological evidence of BPH is found in 8% of men 
aged between 31 and 40 years, and the proportion increases 
to more than 70% of men by the seventh decade of life. The 
average prostate weight increases from approximately 20 
g at the age of 40 to 38.8 g in men older than 80 [13]. In addi-
tion, there is a close relationship between prostate volume 
and LUTS. LUTS based on IPSS is mirrored by changes in 
prostate volume, and the changes in LUTS and other meas-
ures of urinary function are associated with change in pros-
tate volume even though there is no definite proportion be-
tween prostate volume and LUTS or IPSS [14]. In general, 
a decrease in prostate volume by any treatment method oc-
curs simultaneously with improvement in LUTS.
It was suggested several years ago that prostate in-
flammation may be a third component in determining the 
association between BPH and LUTS. There is even evi-
dence of a weak relationship between the degree of LUTS 
and the degree of chronic inflammation [5,15]. This is a re-
minder that detection of prostatitis in patients with LUTS 
is simply important. Sometimes, pyuria is combined with 
prostatitis, but in most cases of chronic prostatitis, there 
is no evidence of urinary tract infection. Elevated PSA can 
be a clue to chronic prostatitis [16]. Ninety-nine percent of 
patients with PSA over 4 ng/ml without prostate cancer 
showed chronic prostatitis compared with 77% of the con-
trol group in research by Nadler et al. [17]. Mostly, how-
ever, there is no specific laboratory evidence for chronic 
prostatitis or a definite tool for measuring improvement. 
This is why consideration of prostatitis in patients with 
LUTS has priority in the diagnostic schema. 
As we discussed above, BPH and prostatitis are the most 
common benign diseases of the prostate (and probably the 
entire genitourinary tract) and affect a significant majority 
of men over time [18]. There are many approaches to the 
diagnosis of BPH, and prostate volume detection is the 
most important. Prostate volume is detectable precisely to-
day by transrectal ultrasound. Clinical use of 3D ultra-
sound has spread rapidly in many specialties, including ur-
ology, over the past 10 years. In particular, the clinical ap-
plication of volume estimation by 3D ultrasound has re-
cently gained much attention. This precise method of pros-
tate volume measurement has shown more satisfactory re-
sults recently in BPH treatment [19]. With the use of all 
these volume-detecting methods, LUTS without prostate 
hyperplasia or any other obstruction of urine flow should 
be considered in connection to prostate inflammations 
such as chronic prostatitis/chronic pelvic pain syndrome 
(CP/CPPS).
Confirmative differential diagnosis of BPH and prostati-
tis is difficult because the symptoms are similar. More than 
6% of visiting patients with a primary diagnosis of prostati-
tis have a concomitant diagnosis of BPH. Some older men 
with LUTS may be incorrectly diagnosed with BPH simply 
because of their symptoms and their old age, or they may 
have prostatitis as well as BPH [20]. Recently, there has 
been much research on this. In many cases of LUTS, pros-
tate inflammation is combined with BPH. The association 
between BPH and intraprostatic inflammation was first 
proposed on the basis of the histological coexistence of hy-
perplastic nodules and chronic inflammatory infiltrates in Korean J Urol 2012;53:109-113
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a high proportion of BPH tissues [5,21]. In a subgroup of 
randomly selected patients from the reduction by dutas-
teride of prostate cancer events trial, the association be-
tween inflammation and the severity of BPH symptoms 
was described [22]. Now, the relationship between LUTS 
and BPH is gradually being clarified. In that mechanism, 
continuous prostate enlargement can be a result of re-
current prostate inflammation. Moreover, this is another 
reason to control prostatitis as well as prostatic hyper-
plasia.
Of course, there are some differences between the symp-
toms of BPH and those of prostatitis. The symptoms of BPH 
are various but those of prostatitis are mainly irritative 
symptoms such as chronic pelvic pain. Accordingly, LUTS 
may be divided into two categories, namely, obstructive 
and irritative symptoms in order to compare BPH with 
prostatitis.
In a symptomatic approach to LUTS, prostatitis without 
evidence of bacterial infection is a dilemma for therapeutic 
modalities. A multidisciplinary approach to patients with 
chronic prostatitis is a recent therapeutic consideration 
[23].
Chronic prostatitis is a long-standing disease resistant 
to medication therapy. The age of patients with chronic 
prostatitis is not limited to older men as in BPH. In addi-
tion, prostatitis patients are generally treated in the out-
patient setting [16]. Many enrolled patients disappear, 
come to the clinic very irregularly, or receive concomitant 
management from other hospitals. Some of the cases are 
prescribed antibiotics such as quinolones or alpha-block-
ers [24,25], and for such cases there was a little improve-
ment in symptoms and quality of life. However, most of 
them were not that effective. Nevertheless, most CP/CPPS 
patients needed to be managed aggressively by various 
medications, such as antibiotics, analgesics, and anti-
depressants or other invasive managements, such as botu-
linum injection as well as the current medications [23,26].
It is confusing that the prostatitis of the enrolled patients 
was found incidentally, and this suggests that these cases 
should be classified as CP/CPPS. Also, this study was a ret-
rospective analysis, which means that case-control study 
was difficult and the initially enrolled cases were too lim-
ited to be engaged. For instance, some items were discarded 
or skipped from the medical records. Also, it is virtually im-
possible to confirm CP/CPPS retrospectively; thus, the con-
firmative diagnostic method was pathologic confirmation 
of prostate tissues, and this limitation resulted in some 
problems such as the relatively higher PSA level of the en-
rolled cases than of the normal population or the narrowed 
range of BPH patients who were managed operatively. 
Practically, however, a larger number of patients with 
LUTS do not need operative procedures. Most BPH pa-
tients receive alpha blockers and 5-alpha reductase in-
hibitors to reduce their LUTS, and prostatitis patients pri-
marily receive antibiotics, with additional prescription of 
alpha blockers. Because BPH and prostatitis share some 
symptoms and features, many physicians handle prostati-
tis and BPH medications indistinctively. This may make 
the results confusing or distorted when the prostate vol-
ume is relatively small.
In this study, post-managed urodynamic and pres-
sure-flow analysis might have been included for quantifi-
cation, classification of LUTS origin, or exclusion of neuro-
genic bladder for all the patients, but as we discussed 
above, chronic prostatitis patients are hard to follow up and 
are resistant to repetitive consultation. Therefore, we had 
to exclude all patients with a history of neurologic or psy-
chological problems or with suspicious neurogenic bladder 
by selective post-managed urodynamic study. However, 
because the IPSS is a well-designed voiding symptom scal-
ing system, we at least achieved subjective quantification 
of symptoms.
Pathologic confirmation of benign prostate enlarge-
ment, prostatitis, and combined BPH with prostatitis was 
made by pathologic specialists, but the severity of in-
flammation was not recorded. The severity of inflamma-
tion is known to be a factor affecting LUTS [15].
Prescribed medications could affect LUTS. In this study, 
the patients did not have any urologic or antibiotic medi-
cation history for their LUTS within 6 months. However, 
they were prescribed antibiotics for 3 days before prostate 
biopsy and prophylactic antibiotics for transurethral pros-
tate resection. This could have affected the results of this 
study.
A well-designed prospective study is needed to avoid 
these biases. First of all, chronic prostatitis should be diag-
nosed in at least 6 months after the first visit to the clinic. 
Precise prostate volume detection and annual PSA con-
firmation should be included. Prophylactic antibiotics and 
prescription for prostate biopsy should have consensus.
CONCLUSIONS
Prostatitis is a more vulnerable factor for LUTS in patients 
with a normal to moderately enlarged prostate volume. On 
the other hand, for patients with a large prostate volume 
over 50 ml, the volume is a more significant risk factor than 
is prostatitis. 
For counseling and workup of patients with LUTS, pros-
tatitis as a disease entity that can be controlled by medi-
cation and other procedures should be given priority in the 
problem list. In other words, if volume reduction of prostate 
tissue hyperplasia is the target of LUTS with BPH, control-
ling prostatitis is the primary target of any kind of LUTS 
management regardless of whether the prostatitis comes 
with BPH or not.
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